The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells
Affiliations: Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑8655, Japan, Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104‑0045, Japan, Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo 173‑0003, Japan
- Published online on: August 24, 2020 https://doi.org/10.3892/ol.2020.12014
- Article Number: 153
Copyright: © Kojima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.